



**1 of 1**

JAN 09 1991

# Bence Jones Proteins: Powerful Tool for Fundamental Study of Protein Chemistry and Pathophysiology.

F.J. Stevens      A. Solomon†  
M. Schiffer

Biological and Medical Research Division  
Argonne National Laboratory  
Argonne, IL 60439-4833

†University of Tennessee  
Medical Center at Knoxville  
Knoxville, Tennessee 37920-6999

The submitted manuscript has been authored  
by a contractor of the U. S. Government  
under contract No. W-31-109-ENG-38.  
Accordingly, the U. S. Government retains a  
nonexclusive, royalty-free license to publish  
or reproduce the published form of this  
contribution, or allow others to do so, for  
U. S. Government purposes.

## DISCLAIMER

This report was prepared as an account of work sponsored by an agency of the United States Government. Neither the United States Government nor any agency thereof, nor any of their employees, makes any warranty, express or implied, or assumes any legal liability or responsibility for the accuracy, completeness, or usefulness of any information, apparatus, product, or process disclosed, or represents that its use would not infringe privately owned rights. Reference herein to any specific commercial product, process, or service by trade name, trademark, manufacturer, or otherwise does not necessarily constitute or imply its endorsement, recommendation, or favoring by the United States Government or any agency thereof. The views and opinions of authors expressed herein do not necessarily state or reflect those of the United States Government or any agency thereof.

AUG 09 1991  
OSTI  
MASTER

DISTRIBUTION OF THIS DOCUMENT IS UNLIMITED

On November 1, 1845, Dr. Henry Bence Jones received from Dr. Watson a specimen and an accompanying note which stated

The tube contains urine of very high specific gravity; when boiled it becomes highly opaque; on the addition of nitric acid it effervesces, assumes a reddish hue, becomes quite clear, but, as it cools, assumes the consistence and appearance which you see: heat reliquifies it. What is it?<sup>1</sup>

The answer was not elementary. Although the substance subsequently known as Bence Jones protein was chemically analyzed, its unusual temperature-dependent solubility described, and its potential diagnostic relevance for the hematopoietic neoplasm now known as multiple myeloma predicted, more than one hundred years passed before Bence Jones protein was identified as the light chain component of human immunoglobulin.<sup>2</sup>

Bence Jones proteins are typically found in patients with monoclonal plasma cell or related B-cell immunoproliferative disorders, i.e., multiple myeloma, light chain-associated amyloidosis (amyloidosis AL), and occasionally, benign gammopathy, lymphoma, and leukemia. Because of their monoclonal origin and resulting chemical homogeneity, as well as their ready availability, much of the fundamental information on immunoglobulin structure came initially from analysis of Bence Jones proteins and light chains isolated from monoclonal immunoglobulins. Amino acid analyses of these components revealed an N-terminal variable (V) and C-terminal constant (C) domain as well as the existence within the V domain of hypervariable segments that account for the specificity and diversity of antibodies.<sup>3</sup> Over the past three decades, the primary structures of hundreds of light chains (complete and partial), from human and other sources, have been determined, aligned, and archived.<sup>4</sup>

Bence Jones proteins and V<sub>L</sub> dimers were the crystallizable homogeneous

proteins which provided much of the early three-dimensional conformational data that helped explain the structural basis of antibody function.<sup>5-8</sup> Remarkably, a single Bence Jones protein in two solvent systems (low and high ionic strength)<sup>9,10</sup> exhibited significant differences in the interactions of the two monomeric subunits comprising the dimer, resulting in substantial variation in the structure of the antigen combining site under the two solution conditions. This observation led to a prediction that heterogeneity of domain interactions may contribute to antibody-antigen interactions.<sup>11</sup> Experimental support for this hypothesis has come from comparisons of the detailed structures of antibody-antigen complexes.<sup>12,13</sup> The interactions at the interface of the  $V_L$  dimer are a function of primary structure and solution conditions. Study of these interactions has led to new information on the relationship between protein structure and function and, as discussed below, can account for specific pathophysiological properties associated with Bence Jones proteins.

The variability in  $V_L$  primary structure accounts for the diverse and idiosyncratic pathological characteristics of Bence Jones proteins. In many patients, the morbidity of the disease is aggravated by apparent structure-dependent polymerization and deposition tendencies of these proteins, which leads to organ impairment and failure.<sup>14-18</sup> The molecular mechanisms leading to pathological phenomena that include cast formation in nephron tubules, and to polymerization and deposition on tubular and capillary basement membranes, or to amyloid formation accompanied by systemic or organ-specific deposition, are not understood. Although unusual temperature-dependent solubility<sup>1,19</sup> and polymerization<sup>20</sup> properties of Bence Jones proteins have been previously characterized, the relationship of these phenomena to the *in vivo* toxicity has not been evident. Through the use of an experimental animal system in which human Bence Jones proteins are injected into mice, we have shown that these proteins can be deposited in the mouse kidney as casts, basement precipitates, crystals, or

as amyloid comparable to that found in the kidneys of the patients from whom the Bence Jones proteins were obtained. Further evidence for the central role of Bence Jones proteins in the histopathological process has been evidenced by the fact that injection into mice of clinically non-nephrotoxic Bence Jones proteins fails to induce significant nephropathy (Ref. 21 and Solomon, Weiss, & Kattino, manuscript in preparation).

In an attempt to account for the capability of certain Bence Jones proteins to form *in vivo* proteinaceous casts within renal tubules, we have applied an HPLC technique to determine the tendency of these proteins to polymerize *in vitro* and have found a significant correlation between *in vitro* aggregation characteristics of these proteins and their *in vivo* deposition tendency. We posit that these oligomerization properties of Bence Jones proteins are involved in the mechanisms underlying light chain deposition or amyloid formation (Stevens *et al.*, manuscript in preparation). To date, our studies have shown that Bence Jones proteins obtained from patients with light chain-associated nephropathy are capable of higher order aggregation (presumably through interaction between dimers) under size-exclusion chromatography conditions that are representative of the microenvironmental sites of *in vivo* deposition. In contrast, Bence Jones proteins for which no tubular cast formation, basement membrane deposition, or amyloid formation were found clinically, have shown no tendency to aggregate under the same conditions (Myatt & Stevens, manuscript in preparation). Differences in characteristic dimerization and oligomerization properties of proteins produced by individual patients necessarily originate in the limited number of amino acid substitutions that differentiate these molecules of highly conserved three-dimensional structure. The magnitude of these interactions, *i.e.*, the thermodynamic free energy change that accompanies aggregation, is a function of pH, salt concentration, and buffer composition.

The clinical significance of understanding the mechanism of Bence Jones

protein pathology provides a new rationale for basic biophysical study of these polypeptides. The clinical challenge posed by such molecules addresses central issues of protein chemistry: the structural bases of biomolecular recognition and the assembly of protein subunits. In this respect, Bence Jones proteins represent a unique model for the study of fundamental protein chemistry.

Dimerization of Bence Jones proteins provides the basis of the ability of these molecules to mimic the Fab portion of an antibody, which comprises both the light chain and the corresponding V and C domain segments contributed by the immunoglobulin heavy chain. The affinity of the interaction between  $V_L$  domains<sup>22,23</sup> is dependent upon the primary sequence; significant differences in affinity were found as a consequence of amino acid substitutions at a single position in the third hypervariable segment.<sup>23</sup> In the absence of known biological function for light chains, other than their role as an antibody constituent, it has been assumed that self-association of light chains was a fortuitous occurrence, presumably reflecting the ability of light chains to associate with the structurally homologous  $V_H$  domain. Recent evidence suggests that light chains are capable of expressing a B-cell regulatory function.<sup>24,25</sup> If so, then dimerization of light chains may itself have a natural biological significance. Higher order aggregation of Bence Jones proteins provides a pathological functional correlate of primary structure.

Advances in molecular biology make it possible to determine the structural basis of Bence Jones protein pathophysiology, and in so doing, to establish the value of these proteins for experimental analysis of fundamental protein structural and functional relationships. Differences in multiple (solvent-sensitive) interaction properties can be attributed to limited amino acid substitutions that differentiate individual Bence Jones proteins. Because functional immunoglobulin light chains can be expressed in *E. coli*,<sup>26-31</sup> recombinant techniques can be used to construct single-amino-acid variants to test structure-function hypotheses to

identify surfaces responsible for interactions between these proteins. Recombinant human light chains will facilitate quantitative modeling of the consequences of site-specific substitutions of single amino acids. The change in free energy of interaction that results from a single residue substitution provides the primary data needed for detailed theoretical understanding of conformational and functional alterations due to changes in amino acid composition. Design of variant recombinant light chains will be guided by the several hundred archived amino acid sequences<sup>4</sup> that effectively catalog biologically permissible substitutions. Because of their role in immunoglobulin structure, Bence Jones proteins and other light chains represent the most broadly studied family of related proteins.

Combined biophysical, structural, and genetic engineering studies focused on Bence Jones proteins offer a unique experimental strategy to investigate systematically the detailed structural and functional consequences that arise from single amino acid substitutions. Development of this capability has direct significance for protein engineering and for understanding the biomedical consequences of genetic mutation. Knowledge of the detailed structural and functional effects of single amino acid substitutions will help make it possible to predict the three dimensional structure of a protein based on its amino acid sequence.

The clinical objective associated with basic biophysical study of Bence Jones proteins is the development of new therapies to counter the formation of amyloid and other toxic aggregation products. A small molecule that binds specifically to one of the light chain surfaces involved in the pathological aggregation process would limit the development of protein deposition. Thus, if light chain pathologies are related to protein oligomerization, a conceptual basis exists for the identification or design of drugs that could retard or reverse oligomerization-related problems. For the same reasons that analysis of Bence Jones proteins should contribute significantly to understanding energetics and mechanisms of protein folding and macromolecular recognition, this family of proteins repre-



sents a significant tool for basic research into the design of synthetic protein-specific drugs. The experience that can be obtained during identification of pharmaceutical agents that modulate experimentally accessible interactions between immunoglobulin light chains will be relevant to other disease processes that involve pathological assembly of identical protein subunits such as found in non-immunoglobulin forms of amyloidosis, e.g., systemic familial amyloidosis, senile amyloid, Alzheimer's disease, Down's syndrome, diabetes-associated amyloidosis,  $\beta$ 2-microglobulin (dialysis-associated) amyloidosis, and others. Interactions between identical protein subunits are also a feature of the assembly of viral capsids. Thus, systematic study of interactions between small molecules and the diverse family of immunoglobulin light chains may contribute significantly to the development of non-cytotoxic drugs capable of attenuating specific viral infections.

In summary, continued research on Bence Jones proteins provides new insights into the pathogenesis of human light-chain-associated renal and systemic diseases. These studies should also result in fundamental contributions to our understanding of the molecular basis of protein structure and interaction, to protein engineering, and to design of protein-specific synthetic drugs.

Perhaps, by November 1, 1995, the 150-year anniversary of Dr. Watson's seminal observations and query regarding an unusual urinary protein, it will be possible to identify candidate drugs that will reduce the clinical complications associated with the proteins that bear the name of his correspondent — Dr. Henry Bence Jones.

This work was supported by the United States Department of Energy, Office of Health and Environmental Research, under Contract W-31-109-ENG-38, and

by grants from the United States Public Health Service and National Cancer Institute (CA 10056).

- [1] Jones, H. B. *Phil. Trans. R. Soc. London*, 55-62 (1848).
- [2] Edelman, G.M. & Gally, J.A. *J. Exp. Med.*, 116:207-227 (1962).
- [3] Wu, T.T. & Kabat, E.A. *J. Exp. Med.*, 132:211-250 (1970).
- [4] Kabat, E.A., Wu, T.T., Reid-Miller, M., Perry, H.M., & Gottesman, K.S. *Sequences of Proteins of Immunological Interest*. U.S. DHHS, National Institutes of Health (1987).
- [5] Schiffer, M., Girling, R.L., Ely, K.R., & Edmundson, A.B. *Biochemistry*, 124:4620-4631 (1973).
- [6] Epp, O., Colman, P.M., Fehlhammer, H., Bode, W., Schiffer, M., Huber, R., & Palm, W. *Eur. J. Biochem.*, 45:513-524 (1974).
- [7] Fehlhammer, H., Schiffer, M., Epp, O., Colman, P.M., Lattman, E.E., Schwager, P., & Steigemann, W. *Biophys. Struct. Mechanism*, 1:139-146 (1975).
- [8] Colman, P.M., Schramm, H.J., & Guss, J.M. *J. Mol. Biol.*, 116:73-79 (1977).
- [9] Chang, C.-H, Short, M.T, Westholm, F.A., Stevens, F.J., Wang, B.-C., Furey, W., Solomon, A., & Schiffer, M. *Biochemistry*, 24:4890-4897 (1985).

- [10] Schiffer, M., Ainsworth, C., Xu, Z.-B., Carperos, W., Olsen, K., Solomon, A., Stevens, F.J., & Chang, C.-H. *Biochemistry*, 28:4066–4072 (1989).
- [11] Stevens, F.J., Chang, C.-H., & Schiffer, M. *Proc. Natl. Acad. Sci. USA*, 85:6895–6899 (1988).
- [12] Bhat, T.N., Bentley, G.A., Fischmann, T.O., Boulet, G., & Poljak, R.T. *Nature*, 347:483–485 (1990).
- [13] Colman, P.M. *Adv. Immunol.*, 43:99–132 (1988).
- [14] Solomon, A. *New England J. Med.*, 306:605–607 (1982).
- [15] Solomon, A. *Semin. Oncol.*, 13:341–349 (1986).
- [16] Feiner, H.D. *Human Pathol.*, 19:1255–1272 (1988).
- [17] Gallo, G.R., Picken, M., Buxbaum, J.N., & Frangione, B. *Semin. Hematol.*, 26:234–245 (1989).
- [18] Buxbaum, J.N., Chuba, J.V., Hellman, G.C., Solomon, A., & Gallo, G.R. *Ann. Int. Med.*, 112:455–464 (1990).
- [19] Putnam, F.W., Easley, C., Lynn, L., Ritchie, A., & Phelps, R. *Arch. Biochem. Biophys.*, 83:115–130 (1959).
- [20] Neet, K.E. & Putnam, F.W. *J. Biol. Chem.*, 241:2320–2325 (1966).
- [21] Solomon, A. & Weiss, D.T. *In The Kidney in Plasma Cell Dyscrasias*. L. Minnetti, G.D.'Amico, and C. Ponticelli, Eds., Kluwer Academic Publishers, Dordrecht, The Netherlands, 1988, pp 3–18.
- [22] Maeda, H., Steffan, E., & Engel, J. *Biophys. Chem.*, 9:57–64 (1978).

- [23] Stevens, F.J., Westholm, F.A., Solomon, A., & Schiffer, M. *Proc. Natl. Acad. Sci. USA*, 77:1144–1148 (1980).
- [24] Joshua, D.E., Ioannidis, R.A., Brown, R.D., Francis, S.E., Gibson, J., & Kronenberg, H. *Am. J. Hematology*, 29:5–11, (1988).
- [25] Ioannidis, R.A., Joshua, D.E., Warburton, P.T., Francis, S.E., Brown, R.D., Gibson, J., & Kronenberg, H. *Hematol. Pathol.*, 3:169–175 (1989).
- [26] Skerra, A. & Pluckthun, A. *Science*, 240:1038–1041 (1988).
- [27] Ward, E.S., Gussow, D., Griffiths, A.D., Jones, P.T., & Winter, G. *Nature*, 341:544–546 (1989).
- [28] Sharon, J. *Proc. Natl. Acad. Sci.*, 87:4814–4817 (1990).
- [29] Anand, N.N., Dubuc, G., Mandal, S., Phipps, J., Gidney, M.A.J., Sinnott, B., Young, N.M., MacKenzie, C.R., Bundle, D.R., & Narang, S.A. *Protein Engin.*, 3:541–546 (1990).
- [30] Glockshuber, R., Malia, M., Pfitzinger, I., & Pluckthun, A. *Biochemistry*, 29:1362–1367 (1990).
- [31] Glockshuber, R., Steipe, B., Huber, R., & Pluckthun, A. *J. Mol. Biol.*, 213:613–615 (1990).

**DATE  
FILMED**

11 / 23 / 93

**END**